Dendritic cell-based therapeutic cancer vaccines: What we have and what we need

Future Oncology

Volumn 5, Issue 3, 2009, Pages 379-390

  Kalinski, Pawel ^a   Urban, Julie ^a   Narang, Rahul ^a   Berk, Erik ^a   Wieckowski, Ewa ^a   Muthuswamy, Ravikumar ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Cancer; Clinical trials; Colorectal cancer; CTL; Dendritic cells; Immunotherapy; Melanoma; NK cells; Ovarian cancer; Prostate cancer; Signal3; Signal4; Th1; Vaccines

Indexed keywords

ANTIBODY; CANCER VACCINE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; LYMPHOCYTE HOMING; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TUMOR CELL; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 66949138572     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.6     Document Type: Review

References (144)

1. Nauts HC: Bacteria and cancer: antagonisms and benefits. Cancer Surv. 8, 713-723 (1989).
2. Burnet FM: The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970).
3. Stutman O: Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183, 534-536 (1974).
4. Banckreau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005).
5. Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004).
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. 10, 475-480 (2004).
7. Gilboa E: The promise of cancer vaccines. Nat. Rev. Cancer 4, 401-411 (2004).
8. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
9. Srivastava PK: Therapeutic cancer vaccines. Curr. Opin. Immunol. 18, 201-205 (2006).
10. Rabinovich GA, Gabrilovich D, Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007).
11. Gabrilovich D: Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
12. Harzstark AL, Small EJ: Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015-(Provenge). Expert Opin. Biol. Ther. 7, 1275-1280 (2007).
13. Pilla L, Patuzzo R, Rivoltini L et al.: A Phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol. Immunother. 55, 958-968 (2006).
14. Small EJ, Schellhammer PF, Higano CS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24. 3089-3094 (2006).
15. Peoples GF, Holmes JP, Hueman MT et al.: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14, 797-803 (2008).
16. Lurquin C, Iethe B, De Plaen E et al.: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201, 249-257 (2005).
17. Godelaine D, Carrasco J, Lucas S et al.: Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J. Immunol. 171, 4893-4897 (2003).
18. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
19. Rosenberg SA: Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350, 1461-1463 (2004).
20. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187 (1997).
21. Steinman RM: The dendritic cell system and its role in immunogenecity. Annu. Rev. Immunol. 9, 271-296 (1991).
22. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature 449, 419-426 (2007).
23. Gabrilovich D, Pisarev V: Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets 4, 525-536 (2003).
24. Yang L, Carbone DP: Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92, 13-27 (2004).
25. Pinzon-Charry A, Maxwell T, Lopez JA: Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83, 451-461 (2005).
26. Uchida K, Schneider S, Yochim JM et al.: Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 11, 3363-3368 (2005).
27. Williams C, Shattuck-Brandt RL, DuBois RN: The role of COX-2 in intestinal cancer. Ann. N. Y. Acad. Sci. 889, 72-83 (1999).
28. Inaba T, Sano H, Kawahito Y et al.: Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc. Natl Acad. Sci. USA 100, 2736-2741 (2003).
29. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 10, 8465-8471 (2004).
30. Almand B, Clark JI, Nikitina E et al.: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001).
31. Almand B, Resser JR, Lindman B et al.: Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
32. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells. J. Immunol. 166, 5398-5406 (2001).
33. + natural suppressor cells. Int. J. Cancer 74, 69-74 (1997).
34. Bell D, Chomarat P, Broyles D et al.: In breast, carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190, 1417-1426 (1999).
35. Toriyama K, Wen DR, Paul E, Cochran AJ: Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J. Invest-Dermatol. 100, 269S-273S (1993).
36. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4, 585-593 (1998).
37. Zou W, Machelon V, Coulomb-L'Hefmin A et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339-1346 (2001).
38. Della Bella S, Gennaro M, Vaccari M et al.: Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89, 1463-1472 (2003).
39. Nefedova Y, Huang M, Kusmartsev S et al.: Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172, 464-474 (2004).
40. Oyama T, Ran S, Ishida T et al.: Vascular endothelial growth factor affects-dendritic cell maturation through the inhibition of nuclear factor-κB activadon in the nemopoietic progenitor cells. J. Immunol. 160, 1224-1232 (1998).
41. Esche C, Lokshin A, Shurin GV et al.: Tumor's other immune targets: dendritic cells. J. Leukoc. Biol. 66, 336-344 (1999).
42. Pirtskhalaishvili G, Shurin GV, Esche C et al.: Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br. J. Cancer 83, 506-513 (2000).
43. Kitajima T, Ariizumi K, Bergstresser PR, Takashima A: Ultraviolet B radiation sensitizes a murine epidermal dendritic cell line (XS52) to undergo apoptosis upon antigen presentation to T cells. J. Immunol. 157, 3312-3316 (1996).
44. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA, Pauli G: Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-α, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25, 1943-1950 (1995).
45. Bonham CA, Lu L, Li Y, Hoffman RA, Simmons RL, Thomson AW: Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation 61, 1871-1877 (1996).
46. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA: Ceramide mediates tumor-induced dendritic cell apoptosis. J. Immunol. 167, 3773-3784 (2001).
47. Mayordomo JI, Zorina T, Storkus WJ et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302 (1995).
48. Steinman RM, Adams JC, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J. Exp. Med. 141, 804-820 (1975).
49. Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue discribution. J. Exp. Med. 137, 1142-1162 (1973).
50. Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. II Functional properties in vitro. J. Exp. Med. 139, 380-397 (1974).
51. Steinman RM, Lustig DS, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J. Exp. Med. 139, 1431-1445 (1974).
52. Fujii S, Shimizu K, Hemmi H et al.: Glycolipid α-C-galactasylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl Acad. Sci. USA 103, 11252-11257 (2006).
53. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20, 561-567 (1999).
54. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML: Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J. Immunol. 162, 3231-3236 (1999).
55. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P: Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164, 4507-4512 (2000).
56. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 161, 2804-2809 (1998).
57. Hsu FJ, Benike C, Fagnoni F et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58 (1996).
58. Nestle FO, Alijagic S, Gilliet M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
59. Nestle FO, Farkas A, Conrad C: Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opir. Immunol. 17, 163-169 (2005).
60. Pardoll DM: Cancer vaccines. Nat. Med. 4, 525-531 (1998).
61. Parmiani G, Pilla L, Castelli C, Rivoltini L: Vaccination of patients with solid tumours. Ann. Oncol. 14, 817-824 (2003).
62. Steinman RM: Dendritic cells and immune-based therapies. Exp. Hematol. 24, 859-862 (1996).
63. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94, 459-473 (2001).
64. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
65. Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147 (2003).
66. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187 (1997).
67. Kapsenberg ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3, 984-993 (2003).
68. Ikeda H, Chamoto K, Tsuji T et al.: The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 95, 697-703 (2004).
69. Pulendran B: Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29, 187-196 (2004).
70. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
71. Palucka K, Banchereau J: How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14, 420-431 (2002).
72. + monocyte-derived dendritic cells and the implications for cancer vaccines. Crit. Rev. Immunol. 21, 157-178 (2001).
73. Kalinski P, Moser M: Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5, 251-260 (2005).
74. Mora JR, Bono MR, Manjunath N et al.: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
75. Mora JR, Cheng G, Picarells D, Briskin M, Buchanan N, von Andrian UH: Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J. Exp. Med. 201, 303-316 (2005).
76. Mora JR, von Andrian UH: Retinoic acid: an educational "vitamin elixir" for gut-seeking T cells. Immunity 21, 458-460 (2004).
77. Schaerli P, Loctscher P, Moser B: Cutting edge: induction of follicular homing precedes effector Th cell development. J. Immunol. 167, 6082-6086 (2001).
78. Stagg AJ, Kamm MA, Knight SC: Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur. J. Immunol. 32, 1445-1454 (2002).
79. + T cells. Immunol. Rev. 186, 221-233 (2002).
80. Calzascia T, Masson F, Di Berardino-Besson W et al.: Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22, 175-184 (2005).
81. Fernandez NC, Lozier A, Flament C et al.: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5, 405-411 (1999).
82. Dhodapkar MY, Steinman RM, Sapp M et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173-180 (1999).
83. Adema GJ, de Vries IJ, Punt CJ, Figdor CG: Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 17, 170-174 (2005).
84. De Vries IJ, Krooshoop DJ, Scharenborg NM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63, 12-17 (2003).
85. Zitvogel L, Mayordomo JI, Tjandrawan T et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
86. Furumoto K, Arii S, Yamasaki S et al.: Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int. J. Cancer 87, 665-672 (2000).
87. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59, 4035-4041 (1999).
88. de Vries IJ, Lesterhuis WJ, Scharenborg NM et al.: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9, 5091-5100 (2003).
89. Jonuleit H, Kuhn U, Muller G et al.: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J. Immunol. 27, 3135-3142 (1997).
90. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: impact on priming of TH1 TH2 and nonpolarized T cells. Nat. Immunol. 1, 311-316 (2000).
91. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al.: α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937 (2004).
92. Luft T, Jefford M, Luetjens P et al.: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100, 1362-1372 (2002).
93. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354-1361 (2002).
94. Kalinski P, Mailliard RB, Giermasz A et al.: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. 5, 1303-1315 (2005).
95. + T cells in the development of T helper type 1 responses. J. Exp. Med. 195, 473-483 (2002).
96. Mailliard RB, Son YI, Redlinger R et al.: Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function, J. Immunol. 171, 2366-2373 (2003).
97. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 171, 2251-2261 (2003).
98. + T cell responses in vitro. J. Immunother. 30, 75-82 (2007).
99. + T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 36, 137-146 (2006).
100. Ten Brinke A, Karsten ML, Dieker MC, Zwaginga JJ, van Ham SM: The clinical grade maturation cocktail monophosphoryl lipid A plus IFNγ generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 25, 7145-7152 (2007).
101. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P: Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68, 5972-5978 (2008).
102. + regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191-201 (2007).
103. + regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 212, 314-329 (2006).
104. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235-247 (2003).
105. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM: Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108, 2655-2661 (2006).
106. + regulatory T cells in vivo in humans. Blood 100, 174-177 (2002).
107. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P: Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol. 84(1), 319-325 (2008).
108. Giermasz AS, Urban JA, Nakamura Y et al.: Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Clin. Immunol. Immunother. (2009) (Epub ahead of print).
109. Cerundolo V, Salio M: Harnessing NKT cells for therapeutic applications. Curr. Top. Microbiol. Immunol. 314, 325-340 (2007).
110. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171, 5140-5147 (2003).
111. Liu K, Idoyaga J, Charalambous A et al.: Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med. 202, 1507-1516 (2005).
112. Hermans IF, Silk JD, Gileadi U et al.: Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J. Immunol. 178, 2721-2729 (2007).
113. Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat. Immunol. 3, 867-874 (2002).
114. + NK helper cells. J. Exp. Med. 202, 941-953 (2005).
115. Watchmaker P, Urban J, Berk E et al.: Memory CD8+ T cells protect dendritic cells from CTL killing. J. Immunol. 180, 3857-3865 (2008).
116. Thomas MJ, Noble A, Sawicka E, Askenase PW, Kemeny DM: CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation. J. Immunol. 168, 216-223 (2002).
117. + T cells support the induction of therapeutic cancer immunity. Cancer Res. 67, 10012-10018 (2007).
118. Steinman RM: Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J. Med. 68, 160-166 (2001).
119. + T cell immunity in mice with anti-dendricic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203, 607-617 (2006).
120. Pulendran B, Smith JL, Caspafy G et al.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad. Sci. USA 96, 1036-1041 (1999).
121. + dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
122. + progenitor cells with flt3 ligand, c-kit ligand GM-CSF IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. J. Immunother. 23, 48-58 (2000).
123. Min YH, Lee ST, Choi KM et al.: Ex vivo generation of functional dendritic cells from mobilized CD34+ hematopoietic stem cells. Yonsei Med. J. 39, 328-338 (1998).
124. Berg EL, Goldstein LA, Jutila MA et al.: Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic. Immunol. Rev. 108, 5-18 (1989).
125. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC: ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 349, 796-799 (1991).
126. Picker LJ, Terstappen LW, Rott LS, Streeter PR, Stein H, Butcher EC: Differential expression of homing-associated adhesion molecules by T cell subsets in man. J. Immunol. 145, 3247-3255 (1990).
127. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR, Terstappen LW: Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J. Immunol. 150, 1122-1136 (1993).
128. Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177, 134-140 (2000).
129. Sallusto F, Mackay CR: Chemoattractants and their receptors in homeostasis and inflammation. Curr. Opin. Immunol. 16, 724-731 (2004).
130. Sallus to F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620 (2000).
131. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W: Selective generation of gut tropic T cells in gut-associatvd lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. 198, 963-969 (2003).
132. Sigmundsdottir H, Pan J, Debes GF et al.: DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285-293 (2007).
133. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY: Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
134. + T cells in melanoma patients receiving interleukin 12. Cancer Res. 60, 3559-3568 (2000).
135. Berger TG, Haendle I, Schrama D et al.: Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int. J. Cancer 111, 229-237 (2004).
136. Piras F, Colombari R, Minerba L et al.: The predictive value of CD8 CD4 CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104, 1246-1254 (2005).
137. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
138. Galon J, Fridman WH, Pages F: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 67, 1883-1886 (2007).
139. Pages F, Berger A, Camus M et al.: Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666 (2005).
140. Haanen JB, Baars A, Gomez R et al.: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55, 451-458 (2006).
141. Mullins IM, Slingluff CL, Lee JK et al.: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 64, 7697-7701 (2004).
142. Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949 (2004).
143. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer R: Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heAvy infiltration of T cells in human malignant melanoma. J. Pathol. 189, 552-558 (1999).
144. + T cells in lymphocyte-rich gastric carcinoma. J. Pathol. 217, 21-31 (2009).